Inspyr Therapeutics

Inspyr Therapeutics (formerly known as GenSpera) is a development-stage pharmaceutical company focused on therapeutics that deliver a cancer-destroying drug directly to the tumor or its supporting environment, the tumor vasculature. The Company's prodrug technology renders the drug inactive until it encounters the programmed target, thereby delivering the cytotoxin directly to cancer or the vessels that support it, while potentially avoiding the side effects associated with current chemotherapies. Inspyr Therapeutics also holds patents on prodrug candidates that target the prostate-specific enzymes Prostate Specific Antigen (PSA) and Human Glandular Kallikrein (hK2). These candidates are expected to be useful in the treatment of prostate cancer.